NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 7,505 call options on the company. This is an increase of approximately 962% compared to the typical volume of 707 call options.
Insider Activity at NewAmsterdam Pharma
In other NewAmsterdam Pharma news, insider Johannes Kastelein sold 125,000 shares of NewAmsterdam Pharma stock in a transaction on Monday, August 24th. The stock was sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the completion of the transaction, the insider owned 69,302 shares in the company, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Davidson bought 10,000 shares of the company’s stock in a transaction on Monday, September 14th. The stock was bought at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the acquisition, the chief executive officer directly owned 792,923 shares of the company’s stock, valued at approximately $17,959,705.95. This represents a 1.28% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 176,846 shares of company stock valued at $4,661,919 in the last 90 days. Corporate insiders own 12.74% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC boosted its holdings in NewAmsterdam Pharma by 43.7% in the third quarter. Parallel Advisors LLC now owns 2,012 shares of the company’s stock worth $49,000 after purchasing an additional 612 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in NewAmsterdam Pharma by 4.6% during the 3rd quarter. AlphaCentric Advisors LLC now owns 15,549 shares of the company’s stock valued at $378,000 after buying an additional 681 shares during the last quarter. KBC Group NV purchased a new stake in NewAmsterdam Pharma during the 1st quarter valued at $37,000. Kornitzer Capital Management Inc. KS raised its stake in NewAmsterdam Pharma by 1.3% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 141,711 shares of the company’s stock valued at $3,446,000 after buying an additional 1,778 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of NewAmsterdam Pharma by 34.6% during the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company’s stock valued at $564,000 after buying an additional 4,281 shares during the period. Institutional investors own 89.89% of the company’s stock.
NewAmsterdam Pharma Price Performance
NASDAQ NAMS traded down $0.07 during trading hours on Tuesday, hitting $19.39. The company’s stock had a trading volume of 1,364,098 shares, compared to its average volume of 1,207,235. NewAmsterdam Pharma has a 12 month low of $17.90 and a 12 month high of $42.21. The company’s 50 day simple moving average is $21.41 and its two-hundred day simple moving average is $29.12. The company has a market cap of $2.33 billion, a P/E ratio of -11.47 and a beta of 0.15.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.33. NewAmsterdam Pharma had a negative net margin of 789.95% and a negative return on equity of 31.39%. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $8.82 million. As a group, research analysts predict that NewAmsterdam Pharma will post -1.48 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, November 1st. Royal Bank Of Canada reduced their price objective on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, October 5th. Needham & Company LLC decreased their target price on shares of NewAmsterdam Pharma from $48.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, November 5th. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.82.
View Our Latest Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.
Featured Stories
- Five stocks we like better than NewAmsterdam Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
